ST葫芦娃获得盐酸左沙丁胺醇雾化吸入溶液药品注册证书

Core Viewpoint - ST HuLuWa (605199.SH) has received approval from the National Medical Products Administration for the drug registration certificate of Salbutamol Hydrochloride Nebulization Solution, which is intended for the treatment or prevention of bronchospasm caused by reversible airway obstructive diseases in adults and children over 6 years old [1] Group 1 - The approval of Salbutamol Hydrochloride Nebulization Solution marks a significant milestone for the company in expanding its product offerings in the respiratory therapy market [1] - This product is specifically designed to address bronchospasm, which is a common issue in patients with respiratory conditions, thereby potentially increasing the company's market share in this therapeutic area [1] - The indication for use in both adults and children over 6 years old broadens the target patient demographic, enhancing the product's market potential [1]